Neurogene (NasdaqGM:NGNE) 2026 Conference Transcript

Summary of Neurogene Conference Call Company Overview - Company: Neurogene - Focus: Development of genetic medicines for neurological diseases, particularly Rett syndrome [2][3] Core Points and Arguments - Lead Program: NGN-401 for Rett syndrome, a severe disorder primarily affecting girls, with a market opportunity estimated in the billions, targeting 15,000-20,000 patients in the U.S. and Europe [3][4] - Clinical Trials: The Phase 3 trial, named Embolden, is actively enrolling patients aged 3 and older who have completed the regression phase of the disease, with dosing expected to complete in Q2 of the current year [3][4] - Regulatory Interaction: Neurogene has regular interactions with the FDA, participating in the START Pilot program, which provides significant access and feedback on trial design [7][8] - Trial Design: The Embolden trial was designed in close collaboration with the FDA, incorporating feedback from multiple meetings to ensure alignment on key elements [8][9] - Efficacy Data: In the Phase 1/2 trial, 88% of participants showed improvement on the CGI-I score, with an average of 4 developmental milestones gained per participant [23][24] - Safety Profile: A hyper-inflammatory reaction was observed at a higher dose, leading to a reduction in dosage. Robust monitoring procedures are in place to manage potential adverse events [31][32] Important but Overlooked Content - Statistical Success Threshold: A 35% threshold for success has been established based on natural history data, requiring 7 out of 20 participants to be considered responders for statistical success [35] - Market Dynamics: The market for Rett syndrome treatments is large enough to accommodate multiple players, with Neurogene positioning NGN-401 as a best-in-class gene therapy product [38][39] - Financial Position: Neurogene has sufficient capital to fund key clinical and regulatory milestones through Q1 2028, ensuring a runway for upcoming catalysts [41]